Scarica l'app Stockscreener
6.92
1.02%
0.07
Dopo l'orario di chiusura:
6.98
0.06
+0.87%
Precedente Chiudi:
$6.85
Aprire:
$6.96
Volume 24 ore:
1.28M
Relative Volume:
1.32
Capitalizzazione di mercato:
$346.71M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-4.0947
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
+12.52%
1M Prestazione:
+40.08%
6M Prestazione:
+3.83%
1 anno Prestazione:
+5.33%
Intervallo 1D:
$6.8088
$7.25
Intervallo di 1 settimana:
$5.78
$7.25
Portata 52W:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Confronta CADL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.92 | 308.13M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
What makes Candel Therapeutics Inc. stock price move sharplyShort Squeeze Radar - beatles.ru
Candel Therapeutics (CADL) Has a New Rating from Freedom Capital Markets - The Globe and Mail
Freedom Broker initiates coverage on Candel Therapeutics stock with Buy rating - Investing.com Nigeria
Freedom Broker initiates coverage on Candel Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
(CADL) Investment Report - news.stocktradersdaily.com
Brookline Capital Initiates Candel Therapeutics(CADL.US) With Buy Rating, Announces Target Price $25 - 富途牛牛
Candel Therapeutics added to multiple Russell value indexes By Investing.com - Investing.com South Africa
Brookline Capital initiates Candel Therapeutics stock with Buy rating, $25 target - Investing.com Nigeria
Candel Therapeutics Added To Multiple Russell Value Indexes In 2025 Reconstitution - 富途牛牛
Market movers: Meta, Nvidia, Candel Therapeutics, Ocean Power Technologies... - Proactive financial news
Candel Therapeutics: Russell Inclusion and Clinical Catalysts Drive Biotech Upside - AInvest
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution - The Manila Times
Candel Therapeutics added to multiple Russell value indexes - Investing.com
Candel Therapeutics, Inc. Gains Inclusion in Multiple Russell Value Indexes During 2025 Annual Reconstitution - Nasdaq
Candel Therapeutics Expands Russell Index Presence with - GlobeNewswire
Candel Therapeutics Gains Major Institutional Visibility with 5 New Russell Value Index Additions - Stock Titan
Candel Therapeutics expands Russell Index presence following 2025 reconstitution - Proactive financial news
Candel Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com India
Candel Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com UK
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Market movers: Carnival, Uber, Ideal Power, Candel Therapeutics... - Proactive Investors
Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparations - Proactive financial news
Candel Therapeutics names Charles Schoch as CFO after interim tenure - Proactive financial news
Candel Therapeutics names Charles Schoch as permanent CFO By Investing.com - Investing.com India
Trend Tracker for (CADL) - news.stocktradersdaily.com
Candel Therapeutics Elects New Directors at Annual Meeting - TipRanks
Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030 - GlobeNewswire
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Purchased by Squarepoint Ops LLC - Defense World
Candel Therapeutics appoints new board member ahead of BLA submission By Investing.com - Investing.com South Africa
Small cap wrap: HIVE Digital, TNR Gold, Candel Therapeutics... - Proactive financial news
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., To Board - citybiz
Candel Therapeutics, Inc. Appoints Maha Radhakrishnan to Its Board of Directors - marketscreener.com
Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board - Proactive financial news
Candel Therapeutics appoints new board member ahead of BLA submission - Investing.com
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire
Former Biogen Chief Medical Officer Joins Candel Board as Prostate Cancer Drug Nears FDA Filing - Stock Titan
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Bought by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Takes Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - MSN
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL St - GuruFocus
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL Stock News - GuruFocus
Deutsche Bank AG Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer - MSN
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
Candel Therapeutics (CADL) Gains on FDA RMAT Designation for CAN-2409 - GuruFocus
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy By Investing.com - Investing.com South Africa
(CADL) Trading Report - news.stocktradersdaily.com
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy By Stocktwits - Investing.com India
Small cap wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE... - Proactive financial news
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):